UNSPSC 51102842: Dalfopristin/quinupristin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.

UNSPSC 51102842 Dalfopristin/quinupristin, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally designates a specific antibiotic pharmaceutical product, yet the recent opportunities posted under this code include naloxone procurement (opioid overdose reversal), generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs — none of which constitute dalfopristin/quinupristin procurement. State and local governments soliciting under this code are acquiring emergency response pharmaceuticals, broad-spectrum generic drug supply agreements, and pharmacy benefit program modernization services, rather than the narrow antibiotic product the code name specifies.

Recent activity spans health departments, fire rescue operations, and state pharmacy benefit agencies across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems for the County Community Health Building with quarterly deliveries; the City of Tampa issued ITB 26P00145 in March 2026 for medical and first aid supplies (including airway devices, electrodes, and consumables) for the Fire Department Rescue Division, designated as a sheltered market for certified Small Local Business Enterprises with an estimated contract value of $700,000; the Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026; and the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The mismatch between the code's nominal scope and the actual procurement activity suggests either systematic miscoding in state and local systems or limited relevance of dalfopristin/quinupristin as a procurement driver in these jurisdictions.